Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185902 | 0.92 | HRH3 (0.53) | HRH3GPR119ALKCHEK2CRBN | |
| SCHEMBL15545122 | 0.89 | CRBN (0.44) | HRH3GPR119CRBNDDB1 | |
| SCHEMBL1996530 | 0.85 | GPR119 (0.52) | GPR119CHEK2 | |
| SCHEMBL15532807 | 0.85 | CRBN (0.47) | HRH3CRBNKDM1AALDH1A1 | |
| SCHEMBL1922609 | 0.83 | GPR119 (0.64) | GPR119 | |
| SCHEMBL14779898 | 0.80 | CYP11B2 (0.55) | CHEK2CRBNDDB1 | |
| SCHEMBL14779895 | 0.80 | CYP11B2 (0.55) | CHEK2CRBNDDB1 | |
| SCHEMBL974325 | 0.80 | HRH3 (0.60) | HRH3GPR119ALKCHEK2KDM1A | |
| SCHEMBL4180037 | 0.80 | HRH3 (0.54) | HRH3GPR119ALKCHEK2PRMT5 | |
| SCHEMBL3086234 | 0.79 | HRH3 (0.51) | HRH3GPR119ALKCHEK2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609847-B2 | Dihydroquinolinone derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-12-17 | — | — | US | disclosed |
| WO-2013170072-A2 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NEUROP, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013170072-A2 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NEUROP, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2393802-B1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2393802-B1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-2393802-A1 | DIHYDROQUINOLINONE DERIVATIVES | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090347-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090347-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | PER2, CRY1, BACE1 | HRH3 29/4885GPR119 87/4885ALK 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.